palexia retard toimeainet prolongeeritult vabastav tablett
grunenthal gmbh - tapentadool - toimeainet prolongeeritult vabastav tablett - 150mg 24tk; 150mg 54tk; 150mg 10tk; 150mg 56tk; 150mg 90tk; 150mg 100tk; 150mg 14tk
palexia retard toimeainet prolongeeritult vabastav tablett
grunenthal gmbh - tapentadool - toimeainet prolongeeritult vabastav tablett - 25mg 20tk; 25mg 28tk; 25mg 40tk; 25mg 50tk; 25mg 54tk; 25mg 10tk; 25mg 24tk; 25mg 30tk; 25mg 56tk; 25mg 60tk
palexia retard toimeainet prolongeeritult vabastav tablett
grunenthal gmbh - tapentadool - toimeainet prolongeeritult vabastav tablett - 250mg 50tk; 250mg 10tk; 250mg 40tk; 250mg 14tk; 250mg 30tk; 250mg 60tk
palexia suukaudne lahus
grunenthal gmbh - tapentadool - suukaudne lahus - 20mg 1ml 100ml 1tk
palexia retard toimeainet prolongeeritult vabastav tablett
grunenthal gmbh - tapentadool - toimeainet prolongeeritult vabastav tablett - 50mg 56tk; 50mg 90tk; 50mg 24tk; 50mg 7tk
palexia retard toimeainet prolongeeritult vabastav tablett
grunenthal gmbh - tapentadool - toimeainet prolongeeritult vabastav tablett - 100mg 50tk; 100mg 20tk; 100mg 28tk; 100mg 56tk; 100mg 30tk; 100mg 100tk; 100mg 54tk
palexia retard toimeainet prolongeeritult vabastav tablett
grunenthal gmbh - tapentadool - toimeainet prolongeeritult vabastav tablett - 200mg 28tk; 200mg 10tk; 200mg 54tk; 200mg 24tk; 200mg 30tk; 200mg 20tk; 200mg 60tk; 200mg 100tk; 200mg 14tk
palexia suukaudne lahus
grunenthal gmbh - tapentadool - suukaudne lahus - 4mg 1ml 100ml 1tk
faslodex
astrazeneca ab - fulvestrant - rinnanäärmed - endokriinse ravi, anti-östrogeene - faslodex is indicated , as monotherapy for the treatment of estrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women:, , not previously treated with endocrine therapy, or, with disease relapse on or after adjuvant antiestrogen therapy, or disease progression on antiestrogen therapy. , , , in combination with palbociclib for the treatment of hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative locally advanced or metastatic breast cancer in women who have received prior endocrine therapy. , pre - või perimenopausal naiste kombineeritud ravi palbociclib tuleks koos luteiniseeriva hormooni vabastav hormoon (lhrh) agonist.
forsteo
eli lilly nederland b.v. - teriparatiid - osteoporosis; osteoporosis, postmenopausal - kaltsiumi homöostaas - osteoporoosi ravi postmenopausis naistel ja meestel, kellel on suurem luumurdude risk. postmenopausaalsetel naistel on näidatud selgrooliste ja mittevertebraalsete luumurdude, kuid mitte puusaluumurdude esinemissageduse olulist vähenemist. ravi osteoporoosi seostatakse pidevat süsteemset glükokortikoidi ravi naiste ja meeste suurenenud risk luumurdude.